4.3 Article

Assessment of Quality of Life, Sexual Quality of Life, and Pain Symptoms in Deep Infiltrating Endometriosis Patients With or Without Associated Adenomyosis and the Influence of a Flexible Extended Combined Oral Contraceptive Regimen: Results of a Prospective, Observational Study

Journal

JOURNAL OF SEXUAL MEDICINE
Volume 19, Issue 2, Pages 311-318

Publisher

OXFORD UNIV PRESS
DOI: 10.1016/j.jsxm.2021.11.015

Keywords

Endometriosis; Adenomyosis; Combined Oral Contraceptive; Quality of Life; Sexual Quality of Life

Ask authors/readers for more resources

Women with deep infiltrating endometriosis (DIE) experience impaired quality of life, which may improve with the use of combined oral contraceptives (COCs) containing dienogest and ethinyl estradiol. Patients with DIE and associated adenomyosis (AD) have poorer sexual quality of life and more intense pain symptoms. After 12 months of treatment, both groups showed significant improvement in overall and sexual quality of life.
Background: The quality of life of women with deep infiltrating endometriosis (DIE) is impaired and may improve with combined oral contraceptives (COCs) . Aim: To compare the overall and sexual quality of lif e of patients diagnosed with DIE with or without associated adenomyosis (AD) with that of healthy controls and determine the influence of a COC containing 2 mg dieno-gest/30 /l,g ethinyl estradiol on these aspects. Methods: We enrolled 42 women diagnosed with DIE; 31 diagnosed with DIE + AD by transvaginal ultra-sound, and 39 non-AD/DIE controls. All patients were interviewed regarding pain symptoms (dysmenorrhea, dyspareunia, dyschezia, and dysuria), heavy menstrual bleeding using the Pictorial Blood Loss Assessment Chart, quality of life using the Short Form-36 questionnaire (SF-36), and sexual quality of life using the Sexual Quality of Life-Female questionnaire (SQOL-F) and the Brief Profile of Female Sexual Function (B-PFSF) before starting COCs and after 12 months of treatment. Outcomes: There was significant improvement in overal l and sexual quality of life after treatment in DIE and DIE + AD patients. Results: Non-AD/DIE controls showed significantly higher scores in the B-PFSF, the SQOL-F and the SF-36 questionnaires (P < .05) at baseline versus the other groups. DIE + AD patients showed poorer quality of sexual life and greater intensity in pain symptoms compared with DIE patients. After 12 months of treatment, there was a significant improvement in over a l l and sexual quality of life in the DIE and DIE + AD groups, with improvement in sexual quality of life being slightly greater in DIE + AD patients compared with DIE patients. Pain symptoms also decreased in both groups. Clinical Implications: Patients with DIE + AD showed greater impairment in overall and sexual quality of life compared with patients with isolated DIE which seems to improve with a COC containing 2 mg dienogest/ 30 /l,g ethinyl estradiol. Strengths & limitations: Strengths include the long-term fol l o w up, assessment of the impact of two associated conditions, and administration of the same COC in all patients. Limitations include the relatively small sample size, and the f a c t that we did not assess the effectiveness of a flexible extended COC regimen containing 2 mg dienogest/30 /l,g ethinyl estradiol since the groups were different at baseline. Conclusion: Patients diagnosed with DIE with or without AD hav e a decreased quality of lif e which may improve with a COC containing 2 mg dienogest/30 mu g ethinyl estradiol. Further research is needed to confirm our results. Copyright (C) 2021, International Society of Sexual Medicine. Published by Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available